Stock Forecast

  Enanta Pharmaceuticals, Inc. ( ENTA) Stock. Should you Buy or Sell?    $ 64.04

1.23 (1.88 %)



Enanta Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol ENTA
Price $64.04
Beta 0.584
Volume Avg. $246.79 thousand
Market Cap $1.33 B
52 Week Range $37.59 - $102.0


Enanta Pharmaceuticals, Inc. opened the day at $64.04 which is +'1.88 % on yesterday's close. Enanta Pharmaceuticals, Inc. has a 52 week high of $102.0 and 52 week low of $37.59, which is a difference of $64.41. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.33 B and total net profit is $97074000 which means the company is trading at 13.67 times profit to market capitalization. Theoretically, if you were to buy Enanta Pharmaceuticals, Inc. for $1.33 B, it would take 15 years to get your money back. Enanta Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Enanta Pharmaceuticals, Inc. Stock Forecast - Is Enanta Pharmaceuticals, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -11.052
Dividend Yiel 0.000
Net Profit Margin -1.342


Valuing Enanta Pharmaceuticals, Inc.


Price Book Value Ratio 3.924 Price To Book Ratio 3.924
Price To Sales Ratio 14.832 Price Earnings Ratio -11.052


How liquid is Enanta Pharmaceuticals, Inc.


Current Ratio 13.590
Quick Ratio 13.089


Debt


Debt Ratio 0.123 Debt Equity Ratio 0.140
Long Term Debt To Capitalization 0.062 Total Debt To Capitalization 0.068



Latest news about Enanta Pharmaceuticals, Inc.


Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022 Baird Global Healthcare Conference: Fireside Chat at 9:40

Date : 01/09/2022

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration & CFO Tara Kieffer - SVP, New Product Strategy & Development Conference Call Participants Douglas Buchanan - JMP Securities Brian Skorney - Robert W. Baird & Co. Hannah Adeoye - JPMorgan Chase & Co. Roanna Ruiz - SVB Securities Operator Good afternoon, and welcome to Enanta Pharmaceuticals' Fiscal Third Quarter 2022 Financial Results Conference Call.

Date : 08/08/2022

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 08/08/2022

Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Date : 24/06/2022

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two fireside chats being webcast in June: Jefferies Healthcare Conference: Fireside Chat at 9:00 a.m. ET on June 9, 2022 JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on Ju

Date : 02/06/2022





About Enanta Pharmaceuticals, Inc.


CEO : Dr. Jay Luly
Sector : Healthcare
Industry : Biotechnology

Website : https://www.enanta.com

Exchange : NASDAQ Global Select

Description :

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.


My Newsletter

Sign Up For Updates & Newsletters